Transaktionen anzeigen
Gesundheitswesen

Groupe Serenis has raised capital from BNP Paribas Dev., GSO Capital and Multicroissance

Groupe Serenis has raised US$8 million in equity from BNP Paribas Developpement, Credit Agricole GSO Capital and Multicroissance Banque Populaire Occitane.

Groupe Serenis operates nursing homes, residential units for disabled elderly people and geriatric clinics in the southwest of France, focusing on the high end of the dependency spectrum. A family group incorporated in 1956, Serenis is now taking a new step of development through a partnership with Kaufman&Broad, a French real estate developer, to create a network of nursing homes.

Oaklins' team in France assisted the shareholders of Serenis in this transaction to find private equity investors ready to assist and support them in this new ambitious step in the group's development.

DIENSTLEISTUNG
Beschaffung von Kapital
PARTEIEN

Sprechen Sie mit dem Deal Team

 Raphaël  Petit

Raphaël Petit

Partner

Toulouse, Frankreich
Oaklins France
 Xavier  Auvergnat

Xavier Auvergnat

Director

Toulouse, Frankreich
Oaklins France
 Alexandre  Mantion

Alexandre Mantion

Analyst

Toulouse, Frankreich
Oaklins France

Transaktionen

Maginnis Orthodontics has been acquired by Smile Doctors
Gesundheitswesen

Maginnis Orthodontics has been acquired by Smile Doctors

Maginnis Orthodontics, Inc has been sold to Smile Doctors, LLC.

Mehr erfahren
Global Media Santé has been acquired by SFP Expansion
Private Equity | Gesundheitswesen | TMT

Global Media Santé has been acquired by SFP Expansion

Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.

Mehr erfahren
Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Gesundheitswesen

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Mehr erfahren